Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer
Sponsor: Boehringer Ingelheim
This PHASE2 trial investigates Carcinoma, Renal Cell and is currently completed. Boehringer Ingelheim leads this study, which shows 18 recorded versions since 2009 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
18 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2
▶ Show 13 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jan 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .